GOVX: GeoVax Labs Company Value to Net Income
The market dynamics of GeoVax Labs, Inc. (GOVX) underscore its status as a developer of advanced oncology and infectious disease treatments with a strong scientific reputation. The current indicator stands at 0.00. Business growth relies on MVA technology, while key triggers include government subsidies and the test results of smallpox and COVID-19 drugs. High investor confidence is sustained by authoritative management successfully advancing clinical trials.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_GOVX_-_GeoVax-Labs-Inc._-_PE-Multiple "GOVX: GeoVax Labs, Inc. Business Payback Period 07/04/2022 - 11/15/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for GeoVax Corp (GOVX)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
- earnings and market multiples details:
GOVX - Net Profit|Expected Net Profit GeoVax Labs, Inc.|GOVX - Price to Earnings Ratio|Projected Price to Earnings Ratio GeoVax Labs, Inc.|GOVX - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GeoVax Labs, Inc.|GOVX - Operating profit EBITDA|Net earnings per share (EPS TTM) GeoVax|GOVX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last 12 months geovax.com|GOVX - Net earnings per share growth this year|Expected earnings per share trend next year GeoVax Labs, Inc.
- sales volume and revenue indicators:
Comprehensive company analysis:GeoVax GOVX
Analyzing the operational achievements of GeoVax Labs, Inc. (GOVX) through the company's historical P/E ratio allows for an assessment of the business's market value relative to its annual net income. While this multiple measures the investment payback period, in the biotechnology sector it often serves as an indicator of speculative expectations, reflecting the risks of failing to achieve clinical trial results and a dependence on external government funding.
Key competitors
P/E Multiple Argenx|Price to Earnings Ratio BNTX (BioNTech Group)|ABVX (abivax.com) - Company Value to Net Income|P/E Multiple ADMA (admabiologics.com)|Business Payback Period protagonist-inc.com (PTGX)|IMVT - Price to Earnings Ratio|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Price to Earnings Ratio|Grifols Biemat (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotechnologies|Price to Earnings Ratio CLDX|P/E Multiple auriniapharma.com|Price to Earnings Ratio BioCryst Pharmaceuticals Inc (BCRX)|Vera Therapeutics - Price to Earnings Multiple|P/E Multiple DNTH (dianthustx.com)|Pharvaris Pharma (PHVS) - Market Cap to Earnings|AbCellera Biologics - P/E Multiple|tourmalinebio.com - Market Price to Net Income Ratio|Precigen (PGEN) - Price to Earnings Ratio|Pharming Group - Company Value to Net Income|Price to Earnings Ratio Nektar Therapeutics Inc|UPB (Upstream Pharma) - Market Price to Net Income Ratio|P/E Multiple ZBIO|P/E Multiple immunome.com (IMNM)|P/E Multiple GOSS (gossamerbio.com)|Business Payback Period KalVista Pharma (KALV)|SEPN - Price to Earnings Ratio|Business Payback Period Pieris Pharmaceuticals PVLA|SVRA (Savara Inc.) - Price to Earnings Ratio|Market Cap to Net Income RIGL (Rigel Pharmaceuticals)|ANAB (AnaptysBio) - P/E Multiple|ATXS (Astria Therapeutics, Inc.) - Market Price to Net Income Ratio|Price to Earnings Ratio engene.com (ENGN)|RAPT (RAPT Therapeutics, Inc.) - Company Value to Net Income|Aerovate Therapeutics - Price to Earnings Ratio|Company Value to Net Income ACRS|Kyverna Therapeutics, Inc - P/E Multiple|Market Cap to Net Income TLSA|CABA: P/E Multiple|Price to Earnings Ratio Ventyx Bio|Price to Earnings Ratio Theratechnologies, Inc.|Market Cap to Earnings Avalo Therapeutics AVTX|P/E Multiple ELDN|AGEN (Agenus, Inc.) - Company Value to Net Income|Price to Earnings Ratio Climb Bio, Inc. CLYM|Zura Bio Limited (ZURA) - Market Cap to Earnings|ATYR: Price to Earnings Ratio|adagene.com (ADAG) - Price to Earnings Ratio|Ikena Oncology (IMA) - Price to Earnings Ratio|Price to Earnings Ratio Shattuck Labs, Inc.|Price to Earnings Ratio equilliumbio.com|Price to Earnings Ratio connectbiopharm.com (CNTB)|P/E Multiple IMUX|Business Payback Period Atara Bio|Price to Earnings Ratio InflaRx N.V. IFRX|X4 Pharmaceuticals - Price to Earnings Ratio|ACET: Price to Earnings Ratio|Company Value to Net Income CELU (celularity.com)|INMB: P/E Multiple|BRNS: Market Price to Net Income Ratio|KZR (Kezar Life Sciences, Inc.) - P/E Multiple|SAB Biotherapeutics Inc. (SABS) - Business Payback Period|P/E Multiple AKTX|Price to Earnings Ratio ENLV (Enlivex Therapeutics Ltd)|Price to Earnings Ratio Q32 Bio Inc. QTTB|P/E Multiple edesabiotech.com EDSA|iBio Corporation - P/E Multiple|Company Value to Net Income CARM (carismatx.com)|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Bolt Bio (BOLT) - P/E Multiple|HCWB (HCW Biologics Inc) - P/E Multiple|Price to Earnings Ratio Aptevo Therapeutics (APVO)|P/E Multiple AIM|Market Price to Net Income Ratio ADTX|P/E Multiple GRI (GRI Bio Corporation)|P/E Multiple XORTX Corp XRTX|HIND - Price to Earnings Ratio|Revelation Biosciences (REVB) - Price to Earnings Ratio|INDP (Indaptus Therapeutics, Inc.) - Price to Earnings Ratio|Scinai Immunotherapeutics Ltd (SCNI) - P/E Multiple|CALI (CalciMedica Inc) - P/E Multiple|affimed.com - Market Cap to Net Income|Price to Earnings Ratio allakos.com (ALLK)|P/E Multiple HOOKIPA Pharma, Inc. (HOOK)|IGM Biosciences Inc. - Price to Earnings Ratio|iTeos Therapeutics, Inc. (ITOS) - Market Cap to Earnings|OCEA: Price to Earnings Ratio|Company Value to Net Income TCBP (TC BioPharm (Holdings) PLC)|THRD: P/E Multiple
